Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Consenting patients fulfilling the Poser's clinical criteria for definite MS~2. Age: 18-65, males and females~3. Duration of disease: \>3 years~4. Progressive form of MS: PPMS, SPMS (with/without relapses)~5. EDSS score of 3.5 - 6.5~6. Failure to currently available, registered - first and second line immunomodulatory treatments (at least one).~7. Evidence for new activity of MS during the 3 months before the injection of MSC.~Exclusion Criteria:~1. Patients who were treated with cytotoxic medications during the last 3 months prior to the inclusion.~2. Patients suffering from significant cardiac, renal or hepatic failure or any other disease that may risk the patient or interfere with the ability to interpret the results~3. Patients with active infections~4. Patients with severe cognitive decline or inability to understand and sign the informed consent~5. Patients who received any cellular treatment in the past

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- IT- Treated (Type: EXPERIMENTAL): Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
- IV - Treated (Type: EXPERIMENTAL): Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).